Literature DB >> 29731896

Lentivirus-mediated overexpression of miR-124 suppresses growth and invasion by targeting JAG1 and EZH2 in gastric cancer.

Yangyang Pan1, Aihua Wu2, Fanfan Xu1, Chao Chen1, Lei Jiang2, Rong Jin1,3.   

Abstract

MicroRNA-124 (miR-124) expression is downregulated and has a tumor suppressor role in various types of cancer. The present study revealed that genes encoding miR-124 were frequently methylated and the expression of miR-124 was downregulated in gastric cancer tissues. Stable expression of miR-124 using a lentiviral vector inhibited gastric cancer cell growth, migration and invasion in vitro. In addition, overexpression of miR-124 suppressed gastric cancer cell xenograft growth in nude mice. The expression of the Notch ligand Jagged1 (JAG1) and enhancer of zeste homolog 2 (EZH2) was downregulated upon miR-124 overexpression, and silencing of JAG1 or EZH2 by RNA interference also suppressed gastric cancer cell growth, migration and invasion. Furthermore, expression of fibronectin and vimentin, not able elements of the epithelial-mesenchymal transition, were suppressed by overexpression of miR-124 or inhibition of JAG1 or EZH2 expressions in GC. Together, these results indicated that miR-124 suppressed gastric cancer progression, partly through inhibiting JAG1 and EZH2. Thus, lentivirus-mediated overexpression of miR-124 may be a potential therapeutic strategy against gastric cancer.

Entities:  

Keywords:  Jagged1; enhancer of zeste homolog 2; gastric cancer; lentivirus; microRNA-124

Year:  2018        PMID: 29731896      PMCID: PMC5921033          DOI: 10.3892/ol.2018.8194

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.

Authors:  Fang Zheng; Yi-Ji Liao; Mu-Yan Cai; Yan-Hui Liu; Tian-Hao Liu; Shu-Peng Chen; Xiu-Wu Bian; Xin-Yuan Guan; Marie C Lin; Yi-Xin Zeng; Hsiang-Fu Kung; Dan Xie
Journal:  Gut       Date:  2011-06-14       Impact factor: 23.059

3.  miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1.

Authors:  Jintang Xia; Zhiqiang Wu; Chunping Yu; Weiling He; Haiqing Zheng; Yulong He; Weihua Jian; Lianzhou Chen; Luanjing Zhang; Wen Li
Journal:  J Pathol       Date:  2012-05-23       Impact factor: 7.996

4.  sMicroRNA-1290 inhibits cells proliferation and migration by targeting FOXA1 in gastric cancer cells.

Authors:  Mengxin Lin; Chunmei Shi; Xiaoyan Lin; Jie Pan; Songfei Shen; Zongbin Xu; Qiang Chen
Journal:  Gene       Date:  2016-02-03       Impact factor: 3.688

5.  Codelivery of a miR-124 Mimic and Obatoclax by Cholesterol-Penetratin Micelles Simultaneously Induces Apoptosis and Inhibits Autophagic Flux in Breast Cancer in Vitro and in Vivo.

Authors:  Nan Zhang; Yan Huang; Fengbo Wu; Yinbo Zhao; Xiang Li; Pengfei Shen; Lu Yang; Yan Luo; Li Yang; Gu He
Journal:  Mol Pharm       Date:  2016-06-15       Impact factor: 4.939

6.  The feedback loop between miR-124 and TGF-β pathway plays a significant role in non-small cell lung cancer metastasis.

Authors:  Lidong Zu; Yunjing Xue; Jinglong Wang; Yujie Fu; Xiumin Wang; Gang Xiao; Mingang Hao; Xueqing Sun; Yingying Wang; Guohui Fu; Jianhua Wang
Journal:  Carcinogenesis       Date:  2016-01-27       Impact factor: 4.944

Review 7.  An updated role of microRNA-124 in central nervous system disorders: a review.

Authors:  Yang Sun; Zhu-Min Luo; Xiu-Ming Guo; Ding-Feng Su; Xia Liu
Journal:  Front Cell Neurosci       Date:  2015-05-20       Impact factor: 5.505

8.  NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10.

Authors:  Yingjia Sun; Xinghao Ai; Shengping Shen; Shun Lu
Journal:  Oncotarget       Date:  2015-04-10

Review 9.  Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA.

Authors:  Erin L Hayes; Joan S Lewis-Wambi
Journal:  Breast Cancer Res       Date:  2015-03-17       Impact factor: 6.466

10.  Alterations of epigenetics and microRNAs in cancer and cancer stem cell.

Authors:  Yoshimasa Saito
Journal:  Front Genet       Date:  2014-08-19       Impact factor: 4.599

View more
  6 in total

Review 1.  Targeting Notch in oncology: the path forward.

Authors:  Samarpan Majumder; Judy S Crabtree; Todd E Golde; Lisa M Minter; Barbara A Osborne; Lucio Miele
Journal:  Nat Rev Drug Discov       Date:  2020-12-08       Impact factor: 84.694

2.  Targeting EZH2 as a novel therapeutic strategy for sorafenib-resistant thyroid carcinoma.

Authors:  Zhengshi Wang; Jiaqi Dai; Jie Yan; Yun Zhang; Zhiqiang Yin
Journal:  J Cell Mol Med       Date:  2019-05-13       Impact factor: 5.310

3.  MiR-124-5p Inhibits the Progression of Gastric Cancer by Targeting MIEN1.

Authors:  Feng Liang; HongYan Zhang; YuXuan Qiu; QianRu Xu; KaiYu Jian; Lin Jiang; Fei Wang; Xin Lu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 4.  The long and short non-coding RNAs modulating EZH2 signaling in cancer.

Authors:  Sepideh Mirzaei; Mohammad Hossein Gholami; Kiavash Hushmandi; Farid Hashemi; Amirhossein Zabolian; Israel Canadas; Ali Zarrabi; Noushin Nabavi; Amir Reza Aref; Francesco Crea; Yuzhuo Wang; Milad Ashrafizadeh; Alan Prem Kumar
Journal:  J Hematol Oncol       Date:  2022-03-02       Impact factor: 17.388

Review 5.  Tumor Suppressive Effects of miR-124 and Its Function in Neuronal Development.

Authors:  Rikako Sanuki; Tomonori Yamamura
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

6.  MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway.

Authors:  Yunxiuxiu Xu; Yu Lai; Hanqin Weng; Lanping Tan; Yanshan Li; Guangcheng Chen; Xingxi Luo; Yibiao Ye
Journal:  Aging (Albany NY)       Date:  2019-05-05       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.